Critical Analysis: Sensus Healthcare (NASDAQ:SRTS) and Regenicin (OTCMKTS:RGIN)

Sensus Healthcare (NASDAQ:SRTS) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Profitability

This table compares Sensus Healthcare and Regenicin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	1.99%	1.04%	0.93%
Regenicin	N/A	N/A	N/A

Valuation & Earnings

This table compares Sensus Healthcare and Regenicin’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$24.41 million	2.28	$490,000.00	$0.03	113.04
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A

Sensus Healthcare has higher revenue and earnings than Regenicin.

Insider & Institutional Ownership

25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 0.0% of Regenicin shares are owned by institutional investors. 11.1% of Sensus Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sensus Healthcare and Regenicin, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	0	0	1	0	3.00
Regenicin	0	0	0	0	N/A

Sensus Healthcare currently has a consensus price target of $7.50, suggesting a potential upside of 121.24%. Given Sensus Healthcare’s higher probable upside, equities analysts clearly believe Sensus Healthcare is more favorable than Regenicin.

Summary

Sensus Healthcare beats Regenicin on 9 of the 9 factors compared between the two stocks.

About Sensus Healthcare

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.